Effects of antipsychotics on D3 receptors: A clinical PET study in first episode antipsychotic naive patients with schizophrenia using [ 11C]-(+)-PHNO

Schizophrenia Research

Volumn 131, Issue 1-3, 2011, Pages 63-68

  Mizrahi, Romina ^a,b   Agid, Ofer ^b   Borlido, Carol ^b   Suridjan, Ivonne ^a   Rusjan, Pablo ^a   Houle, Sylvain ^a   Remington, Gary ^b   Wilson, Alan A ^a,b   Kapur, Shitij ^c  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

11C (+) PHNO; Antipsychotic; D3 receptors; Positron Emission Tomography (PET); Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CARBON 11; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; NAXAGOLIDE; NAXAGOLIDE C 11; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; FEMALE; GLOBUS PALLIDUS; HUMAN; IMAGE ANALYSIS; LONGITUDINAL STUDY; MALE; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; SCHIZOPHRENIA; SUBSTANTIA NIGRA; UPREGULATION;

ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; BRAIN; DOPAMINE AGONISTS; HUMANS; MAGNETIC RESONANCE IMAGING; OXAZINES; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, DOPAMINE D3; RISPERIDONE; SCHIZOPHRENIA; YOUNG ADULT;

EID: 80051787669     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2011.05.005     Document Type: Article

References (49)

1. Abi-Saab W., Graff Guerrero A., Redden L., et al. First demonstration of D3 occupancy in humans: blockade of [11C]-(+)-PHNO PET by ABT-925. Paper Presented at: Society of Biological Psychiatry; May 1-3, 2008, Washington, DC 2008.
2. Barnes T.R. A rating scale for drug-induced akathisia. Br. J. Psychiatry 1989, 154:672-676. (May).
3. Boileau I., Guttman M., Rusjan P., et al. Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drug-naive Parkinson's disease. Brain 2009, 132(Pt 5):1366-1375. (May).
4. D'Souza U., McGuffin P., Buckland P.R. Antipsychotic regulation of dopamine D1, D2 and D3 receptor mRNA. Neuropharmacology 1997, 36(11-12):1689-1696. (Nov-Dec).
5. Farde L., Wiesel F.A., Halldin C., Sedvall G. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch. Gen. Psychiatry 1988, 45(1):71-76. (Jan).
6. Florijn W.J., Tarazi F.I., Creese I. Dopamine receptor subtypes: differential regulation after 8months treatment with antipsychotic drugs. J. Pharmacol. Exp. Ther. 1997, 280(2):561-569. (Feb).
7. Freedman S.B., Patel S., Marwood R., Emms F., Seabrook G.R., Knowles M.R., McAllister G. Expression and pharmacological characterization of the human D3 dopamine receptor. J. Pharmacol. Exp. Ther. 1994, 268(1):417-426. (Jan).
8. Gallezot J., Beaver J., Nabulsi N., et al. [11C]-PHNO studies in rhesus monkey: in vivo affinity for D2 and D3 receptors and dosimetry 2009.
9. Gallezot J.-D., Beaver J., Nabeel Nabulsi, et al. [11C]PHNO studies in rhesus monkey: in vivo affinity for D2 and D3 receptors and dosimetry. J. Nucl. Med. 2009, 50(Supplement 2):601.
10. Ginovart N., Galineau L., Willeit M., et al. Binding characteristics and sensitivity to endogenous dopamine of [11C]-(+)-PHNO, a new agonist radiotracer for imaging the high-affinity state of D2 receptors in vivo using positron emission tomography. J. Neurochem. 2006, 97(4):1089-1103. May.
11. Ginovart N., Willeit M., Rusjan P., Graff A., Bloomfield P.M., Houle S., Kapur S., Wilson A.A. Positron emission tomography quantification of [11C]-(+)-PHNO binding in the human brain. J. Cereb. Blood Flow Metab. 2007, 27(4):857-871. (Apr).
12. Girgis R.R., Xu X., Miyake N., Easwaramoorthy B., Gunn R.N., Rabiner E.A., Abi-Dargham A., Slifstein M. In vivo binding of antipsychotics to D(3) and D(2) receptors: a PET study in baboons with [(11)C]-(+)-PHNO. Neuropsychopharmacology 2011, 36(4):887-895. (Mar).
13. Graff-Guerrero A., Mamo D., Shammi C.M., et al. The effect of antipsychotics on the high-affinity state of D2 and D3 receptors: a positron emission tomography study with [11C]-(+)-PHNO. Arch. Gen. Psychiatry 2009, 66(6):606-615. (Jun).
14. Gunn R.N., Gunn S.R., Turkheimer F.E., Aston J.A., Cunningham V.J. Positron emission tomography compartmental models: a basis pursuit strategy for kinetic modeling. J. Cereb. Blood Flow Metab. 2002, 22(12):1425-1439. (Dec).
15. Gurevich E.V., Bordelon Y., Shapiro R.M., Arnold S.E., Gur R.E., Joyce J.N. Mesolimbic dopamine D3 receptors and use of antipsychotics in patients with schizophrenia. A postmortem study. Arch. Gen. Psychiatry 1997, 54(3):225-232. (Mar).
16. Hurley M.J., Stubbs C.M., Jenner P., Marsden C.D. Effect of chronic treatment with typical and atypical neuroleptics on the expression of dopamine D2 and D3 receptors in rat brain. Psychopharmacology (Berl.) 1996, 128(4):362-370. (Dec).
17. Ichise M., Liow J.S., Lu J.Q., et al. Linearized reference tissue parametric imaging methods: application to [11C]DASB positron emission tomography studies of the serotonin transporter in human brain. J. Cereb. Blood Flow Metab. 2003, 23(9):1096.
18. Joyce J.N. D2 but not D3 receptors are elevated after 9 or 11months chronic haloperidol treatment: influence of withdrawal period. Synapse 2001, 40(2):137-144. (May).
19. Kapur S., Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog. Neuropsychopharmacol. Biol. Psychiatry 2003, 27(7):1081-1090. (Oct).
20. Kapur S., Remington G., Zipursky R.B., Wilson A.A., Houle S. The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. Life Sci. 1995, 57(10):PL103-PL107.
21. Kapur S., Zipursky R., Jones C., Remington G., Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am. J. Psychiatry 2000, 157(4):514-520. (Apr).
22. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13(2):261-276.
23. Koeltzow T.E., Xu M., Cooper D.C., Hu X.T., Tonegawa S., Wolf M.E., White F.J. Alterations in dopamine release but not dopamine autoreceptor function in dopamine D3 receptor mutant mice. J. Neurosci. 1998, 18(6):2231-2238. (Mar 15).
24. Lammertsma A.A., Hume S.P. Simplified reference tissue model for PET receptor studies. Neuroimage 1996, 4(3 Pt 1):153-158. (Dec).
25. Levesque D., Martres M.P., Diaz J., Griffon N., Lammers C.H., Sokoloff P., Schwartz J.C. A paradoxical regulation of the dopamine D3 receptor expression suggests the involvement of an anterograde factor from dopamine neurons. Proc. Natl. Acad. Sci. U. S. A. 1995, 92(5):1719-1723. (Feb 28).
26. Martinez D., Slifstein M., Broft A., et al. Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: amphetamine-induced dopamine release in the functional subdivisions of the striatum. J. Cereb. Blood Flow Metab. 2003, 23(3):285-300. (Mar).
27. McCormick P.N., Kapur S., Graff-Guerrero A., Raymond R., Nobrega J.N., Wilson A.A. The antipsychotics olanzapine, risperidone, clozapine, and haloperidol are D2-selective ex vivo but not in vitro. Neuropsychopharmacology 2010, 35(8):1826-1835. (Jul). Electronic publication ahead of print 2010 Apr 21.
28. Narendran R., Slifstein M., Guillin O., et al. Dopamine (D(2/3)) receptor agonist positron emission tomography radiotracer [(11)C]-(+)-PHNO is a D(3) receptor preferring agonist in vivo. Synapse 2006, 60(7):485-495. (Sep).
29. Narendran R., Slifstein M., Guillin O., et al. Dopamine (D2/3) receptor agonist positron emission tomography radiotracer [11C]-(+)-PHNO is a D3 receptor preferring agonist in vivo. Synapse 2006, 60(7):485-495. (Dec 1).
30. Nordstrom A.L., Nyberg S., Olsson H., Farde L. Positron emission tomography finding of a high striatal D2 receptor occupancy in olanzapine-treated patients. Arch. Gen. Psychiatry 1998, 55(3):283-284. (Mar).
31. Parker C., Clarke K., Gee A.D., Gee A., Rabiner E. In vitro characterisation of the high affinity D2/D3 dopamine agonist (+)PhNO. Neuroimage 2006, 31(Supplement 2):T29.
32. Rabiner E.A., Laruelle M. Imaging the D3 receptor in humans in vivo using [11C](+)-PHNO positron emission tomography (PET). Int. J. Neuropsychopharmacol. 2010, 13(3):289-290. (Apr).
33. Rabiner E., Slifstein M., Gunn K., et al. D3 receptor quantification with [11C]-(+)-PHNO PET. Paper Presented at: ACNP 46th Annual Meeting, 2007; Boca Raton, Miami. USA 2007.
34. Rabiner E., Raymond R., Diwan M., McCormick P., Wilson A., Nobrega J. D3 and D2 components of ex vivo regional (+)-PHNO brain binding in wild-type and knock-out mice. Society of Nuclear Medicine Annual Meeting Abstracts. Vol. 48 2007, 113P-b.
35. Rabiner E.A., Slifstein M., Nobrega J., et al. In vivo quantification of regional dopamine-D3 receptor binding potential of (+)-PHNO: studies in non-human primates and transgenic mice. Synapse 2009, 63(9):782-793. (Sep).
36. Rusjan P., Mamo D., Ginovart N., et al. An automated method for the extraction of regional data from PET images. Psychiatry Res. 2006, 147(1):79-89. (Jun 30).
37. Schotte A., Janssen P.F., Gommeren W., Luyten W.H., Leysen J.E. Autoradiographic evidence for the occlusion of rat brain dopamine D3 receptors in vivo. Eur. J. Pharmacol. 1992, 218(2-3):373-375. (Aug 6).
38. Schotte A., Janssen P.F., Bonaventure P., Leysen J.E. Endogenous dopamine limits the binding of antipsychotic drugs to D3 receptors in the rat brain: a quantitative autoradiographic study. Histochem. J. 1996, 28(11):791-799. (Nov).
39. Searle G., Beaver J.D., Comley R.A., et al. Imaging dopamine D3 receptors in the human brain with positron emission tomography, [11C]PHNO, and a selective D3 receptor antagonist. Biol. Psychiatry 2010, 68(4):392-399. (Aug 15).
40. Sheehan D.V., Lecrubier Y., Sheehan K.H., et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 1998, 59(Suppl 20):22-33. (quiz 34-57).
41. Sibley D.R., Mahan L.C., Creese I. Dopamine receptor binding on intact cells. Absence of a high-affinity agonist-receptor binding state. Mol. Pharmacol. 1983, 23(2):295-302. (Mar).
42. Simpson G.M., Angus J.W. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. Suppl. 1970, 212:11-19.
43. Tarazi F.I., Zhang K., Baldessarini R.J. Long-term effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: implications for antipsychotic drug treatment. J. Pharmacol. Exp. Ther. 2001, 297(2):711-717. (May).
44. Tziortzi A.C., Searle G.E., Tzimopoulou S., Salinas C., Beaver J.D., Jenkinson M., Laruelle M., Rabiner E.A., Gunn R.N. Imaging dopamine receptors in humans with [(11)C]-(+)-PHNO: dissection of D3 signal and anatomy. Neuroimage 2011, 54(1):264-277. (Jan 1). Electronic publication ahead of print 2010 Jun 30.
45. Tziortzi A.C., Searle G.E., Tzimopoulou S., et al. Imaging dopamine receptors in humans with [11C]-(+)-PHNO: dissection of D3 signal and anatomy. Neuroimage 2011, 54(1):264-277. (Jan 1).
46. van Vliet L.A., Rodenhuis N., Dijkstra D., et al. Synthesis and pharmacological evaluation of thiopyran analogues of the dopamine D3 receptor-selective agonist (4aR,10bR)-(+)-trans-3,4,4a,10b-tetrahydro-4-n-propyl-2H,5H [1]b enzopyrano[4,3-b]-1,4-oxazin-9-ol (PD 128907). J. Med. Chem. 2000, 43(15):2871-2882. (Jul 27).
47. Wang W., Hahn K.H., Bishop J.F., Gao D.Q., Jose P.A., Mouradian M.M. Up-regulation of D3 dopamine receptor mRNA by neuroleptics. Synapse 1996, 23(3):232-235. (Jul).
48. Willeit M., Ginovart N., Kapur S., Houle S., Hussey D., Seeman P., Wilson A.A. High-affinity states of human brain dopamine D2/3 receptors imaged by the agonist [11C]-(+)-PHNO. Biol. Psychiatry 2006, 59(5):389-394.
49. Wilson A.A., McCormick P., Kapur S., et al. Radiosynthesis and evaluation of [11C]-(+)-4-propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol as a potential radiotracer for in vivo imaging of the dopamine D2 high-affinity state with positron emission tomography. J. Med. Chem. 2005, 48(12):4153-4160.